Navigation Links
Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
Date:6/26/2008

Quark's second siRNA drug delivered systemically

FREMONT, Calif., June 25 /PRNewswire/ -- Quark Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its siRNA drug candidate, DGFi, in kidney transplantation. The Company expects its Phase I/II clinical study for prevention/treatment of Delayed Graft Function (DGF) in kidney transplant patients to begin in the second half of 2008.

DGFi is Quark's second product candidate to enter clinic trials that is systemically administered to patients. The first ever siRNA drug candidate to be delivered systemically in man was Quark's AKIi-5 which is in Phase I clinical trial for acute kidney injury.

The Phase I/II will be a multi center study in which the safety and tolerability of escalating doses of DGFi by a single IV injection in renal transplant patients with DGF. Up to 204 adult kidney transplant recipients will be enrolled in this 2-part study.

"We are pleased with the FDA acceptance of our DGFi IND application for prevention of delayed graft function, which is a very serious medical issue for kidney transplant patients," said Shai Erlich, Ph.D., Chief Development Officer of Quark. "This is an important milestone for us. It marks Quark's third clinical program and the second in which our siRNA drug is administered systemically to patients. This achievement provides further validation of Quark's RNAi based drug discovery approach."

About DGF and Kidney Transplant

Delayed Graft Function (DGF) in renal transplantation is a syndrome caused by ischemia and reperfusion injury. Ischemia reperfusion injury occurs frequently in kidneys that have been outside a living human body and damaged from lack of oxygen in the kidneys that have been blood deprived. In patients with DGF the transplanted kidney does not function properly and requires intervention by dialysis.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... iFitDress.com, the popular online supplier of wedding dresses and special ... black one-shoulder cocktail dresses . In addition, all these ... discounted prices, up to 70% off. , The ... only. You know, we have thousands of frequent callers in ... items can visit our website for more details. The current ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business is ... company announces big discounts on its bamboo mats , ... is the world’s leader in bamboo flooring. According to ... 20, 2015. , The bamboo mats are made from ... All the bamboo strips for the mats are boiled ...
(Date:12/25/2014)... Thompson HealthDay Reporter WEDNESDAY, ... complex chronic illnesses can receive effective, less expensive care from ... access to a team of dedicated health care professionals, a ... seriously ill and need either hospitalization or a trip to ... medical home clinic at the University of Texas in Houston ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... fried foods, snacks, coffee upped chances of disease , , ... amounts of acrylamide, a chemical commonly found in French ... the risk of kidney cancer, especially in smokers, Dutch ... a positive association between dietary acrylamide intake and renal ...
... RIDGE, N.J., May 9 Hooper Holmes,Inc. (Amex: HH ... results for the first quarter ended March 31,2008., For ... to $59.1 million compared to $62.4 million in the first ... million for the first quarter,of 2008, or $(0.01) per share ...
... CHAPEL HILL, N.C., May 9 The cost to ... annual salary, but the long-term cost,to the organization,s Service-Profit ... LLC addresses the effects of turnover on the,bottom line ... employees,engaged to tremendously improve productivity and the overall customer,experience. ...
... CHARLOTTE, N.C., May 9 MedCath Corporation,(Nasdaq: MDTH ... at the Banc of America Securities 2008 Health Care ... Hotel in Las Vegas., MedCath,s senior management will ... Pacific time. The presentation will be web cast live ...
... and Medical Mutual of,Ohio are joining forces to ... management solutions to get injured workers back on,the ... USA will provide workers, compensation,disability, Family Medical Leave ... will provide claims administration and,high-quality comprehensive health and ...
... DC, May 9, 2008 More than 4,000 ... world are expected to convene at a five-day ... major issues facing their profession today. , Strategies ... landscape of healthcare-associated infections (HAIs) and emerging multidrug-resistant ...
Cached Medicine News:Health News:Acrylamide Raises Kidney Cancer Risk 2Health News:Acrylamide Raises Kidney Cancer Risk 3Health News:Hooper Holmes Announces First Quarter 2008 Results 2Health News:Hooper Holmes Announces First Quarter 2008 Results 3Health News:Hooper Holmes Announces First Quarter 2008 Results 4Health News:Hooper Holmes Announces First Quarter 2008 Results 5Health News:Hooper Holmes Announces First Quarter 2008 Results 6Health News:Employee Engagement & Retention: Benchmarking Metrics and Networking Opportunity to Help Solve Today's Workforce Challenges 2Health News:Medical Mutual of Ohio, CareWorks Build a Healthier Workforce 2Health News:APIC conference to focus on patient safety and 'Targeting Zero' initiatives to reduce HAIs 2
(Date:12/24/2014)... /CNW/ -   The ... Canada tests confirmed it contains two undeclared amphetamine-like drug ... The distributor, Empire Health Distribution of Terrebonne, ... stores across Canada .  Jetfuel Superburn ... loss and increased energy. What consumers ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014 Soligenix, ... late-stage biopharmaceutical company developing products that address unmet ... and biodefense, announced today that on December 24, ... offering. The Company raised approximately $2.3 ... intends to use the net proceeds from the ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... DUSA Pharmaceuticals, Inc. ® (Nasdaq GM: DUSA), ... ® Photodynamic Therapy (PDT) and other products focused ... Doman, President and Chief Executive Officer, will present a ... Conference on Thursday, November 18, 2010 at 8:30 a.m. ...
... in Phase... -- ITTIGEN and BERN, Switzerland, November 11, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need to grab ...
Cached Medicine Technology:Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 2Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 3Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 4Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 5Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 6Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 7Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 8Pevion's Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study 9
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
... offers unparalleld speed, providing accurate, reliable ... only 10 ul of blood. Fast ... comprehensive patient care by spending more ... S System is easy-to-use, accurate, convenient, ...
Medicine Products: